The Hematology-Oncology Division at the Wilmot Cancer Institute, located at the University of Rochester, is recruiting an outstanding hematology board-certified/board eligible clinical investigator for an expanding academic and clinical program. He/she will join a team of nonmalignant hematologists who work collaboratively with the other members of the division. A three-year ACGME accredited fellowship program in Hematology/Oncology is offered, which requires a 3-6-month rotation in the nonmalignant hematology
Successful MD, MD/PhD, DO or MBBCh degree applicants will have demonstrated or have the potential for outstanding research relevant to benign, nonmalignant hematology. The applicant will be expected to establish or have established independent or collaborative research programs having the potential for NIH level grant or other lines of funding support. Additionally, the candidate will be expected to advise fellows, residents and medical students and should possess creativity and strong interpersonal skills to work with a diverse faculty will be essential. EOE Minorities/Females/Protected Veterans/Disabled physicians and candidates at all levels of experience (Assistant, Associate, or Full-Professor) are encouraged to apply. Competitive salaries and generous benefits are available.
Please contact: Aram F. Hezel, M.D.
Hematology-Oncology Division Chief
The University of Rochester is committed to fostering, cultivating, and preserving a culture of diversity and inclusion. The University believes that a diverse workforce and inclusive workplace culture enhances the performance of our organization and our ability to fulfill our important missions. The University is committed to fostering and supporting an environment inclusive of people regardless of their race, ethnicity, national origin, gender, sexual orientation, socio-economic status, marital status, age, physical abilities, political affiliation, religious beliefs, or any other non-merit fact, so that all employees feel included, equally valued and supported.